Moleculin Biotech, Inc. announced a collaboration with CIC biomaGUNE for preclinical research on Annamycin for glioblastoma multiforme (GBM).
The research will focus on evaluating the effects of intra-arterial delivery of Annamycin for GBM treatment.
This collaboration aims to address the unmet medical needs in treating central nervous system tumors like GBM.
New Collaboration
Moleculin partners with CIC biomaGUNE for investigating Annamycin's potential in treating GBM.
Research Agreement
The agreement involves supply of Annamycin for preclinical studies on tumor progression in mouse models.
Clinical Activity
Annamycin has shown clinical activity in leukemia, sarcomas, and potential in pancreatic, liver cancers, and now in GBM.
Significance for GBM
The collaboration focuses on addressing the challenges of drug delivery and resistance in GBM, a critical area with limited treatment options.
- The research collaboration signifies Moleculin's commitment to exploring innovative treatments for hard-to-treat cancers like GBM.
- Investigator-initiated studies play a crucial role in advancing potential therapies for patients with limited survival options.
- The focus on intra-arterial delivery of Annamycin highlights the company's dedication to overcoming obstacles in drug delivery for brain tumors.
The partnership with CIC biomaGUNE marks a significant step towards advancing Annamycin's potential in treating GBM, offering hope for patients with this aggressive brain tumor. Moleculin's dedication to addressing the challenges in central nervous system tumors underscores its commitment to improving outcomes for cancer patients.